Lung Cancer

This roundup of recent FDA approvals details the authorization of a new COVID-19 vaccine and options for lung and prostate cancer.

The US Food and Drug Administration has approved the first treatment for a genetic mutation of non-small cell lung cancer, and also approved the diagnostic test for determining multiple genetic mutations...

The FDA has broadened the approval of a non-small cell lung cancer drug, previously approved in 2014.

The FDA approved the first anti-PD-1 therapy to be administered in combination with standard chemotherapy for the treatment of non-small cell lung cancer.

The FDA has approved a new drug for the treatment of patients with metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

The FDA approved osimertinib for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.